In light of the recent development of the Silicon Valley Bank (the “SVB”), I-Mab (the “Company”) today issued a statement confirming that the Company does not hold any cash deposits at SVB or its affiliates, and has no exposure to or business dealings with SVB or its affiliates.
GAITHERSBURG, MD . and SHANGHAI , March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (
Displaying 11 - 14 of 14